Tag Archives: pharmaceutical


DITMo: Hedging without Shorting?

by Peter J de Marigny, DITMo Capital, Newport Beach, CA In a bull market hedged portfolios generally underperform.  The problem for most investors is that reducing risk requires forgoing upside benefit.  Should reducing risk be a question of diversification only?  This is an approach of many financial advisors using mean variance historical returns to show an “efficient frontier” curve.  The […]